↓ Skip to main content

American Association for Cancer Research

Article Metrics

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Overview of attention for article published in Cancer Immunology Research, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy
1 policy source
twitter
18 tweeters

Citations

dimensions_citation
159 Dimensions

Readers on

mendeley
122 Mendeley
Title
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Published in
Cancer Immunology Research, April 2017
DOI 10.1158/2326-6066.cir-16-0325
Pubmed ID
Authors

Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Katy K. Tsai, Kimberly L. Loo, Matthew A. Gubens, Michael Rosenblum, Christina L. Harview, Janis M. Taube, Nathan Handley, Neharika Khurana, Adi Nosrati, Matthew F. Krummel, Andrew Tucker, Eduardo V. Sosa, Phillip J. Sanchez, Nooriel Banayan, Juan C. Osorio, Dan L. Nguyen-Kim, Jeremy Chang, I. Peter Shintaku, Peter D. Boasberg, Emma J. Taylor, Pamela N. Munster, Alain P. Algazi, Bartosz Chmielowski, Reinhard Dummer, Tristan R. Grogan, David Elashoff, Jimmy Hwang, Simone M. Goldinger, Edward B. Garon, Robert H. Pierce, Adil Daud

Abstract

We explored the association between liver metastases, tumor CD8+ T cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the Phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non-small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival (PFS); [objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared to patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation cohort (P = 0.0006). The presence of liver metastasis significantly increased the likelihood of progression (odds ratio 1.852, P < 0.0001). In a subset of biopsied patients (n = 62), liver metastasis was associated with reduced CD8+ T cell density at the invasive tumor margin (liver metastasis+ group, n = 547164.8; liver metastasis -group, n = 1441250.7 P < 0.016). A reduced response rate and shortened PFS was also observed in NSCLC patients with liver metastasis (median PFS, 1.8 months, 95% CI 1.4-2.0), compared to those without liver metastasis (n = 119, median PFS, 4.0 months, 95% CI 2.1-5.1), P = 0.0094. Thus, liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases were associated with reduced marginal CD8+ T cell infiltration, providing a potential mechanism for this outcome.

Twitter Demographics

The data shown below were collected from the profiles of 18 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 122 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 31 25%
Other 16 13%
Student > Ph. D. Student 12 10%
Student > Doctoral Student 12 10%
Student > Master 9 7%
Other 14 11%
Unknown 28 23%
Readers by discipline Count As %
Medicine and Dentistry 44 36%
Biochemistry, Genetics and Molecular Biology 14 11%
Agricultural and Biological Sciences 10 8%
Immunology and Microbiology 8 7%
Arts and Humanities 1 <1%
Other 7 6%
Unknown 38 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2021.
All research outputs
#1,344,346
of 16,948,032 outputs
Outputs from Cancer Immunology Research
#130
of 1,077 outputs
Outputs of similar age
#27,933
of 222,491 outputs
Outputs of similar age from Cancer Immunology Research
#2
of 18 outputs
Altmetric has tracked 16,948,032 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,077 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 222,491 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.